Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Filipits

Showing results (31-40 of 122) with videos related to

Pageof 13
Sort By:
Scientific Reports|January 24, 2017
Electronic State of Sodium trans-[Tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) in Tumor, Liver and Kidney Tissue of a SW480-bearing MouseAmir Blazevic, Alfred A Hummer, Petra Heffeter, et al.
Molecular Cancer Therapeutics|June 11, 2009
Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cellsBeata Herberger, Walter Berger, Harald Puhalla, et al.
The British Journal of Oral & Maxillofacial Surgery|August 15, 2012
Impact of epidermal growth factor receptor, mesenchymal-epithelial transition factor, and insulin-like growth factor receptor 1 expression on survival of patients with oral and oropharyngeal cancerChristos Perisanidis, Fritz Wrba, Anita Brandstetter, et al.
Clinical Breast Cancer|July 2, 2013
Pertuzumab in breast cancer: a systematic reviewFlora Zagouri, Theodoros N Sergentanis, Dimosthenis Chrysikos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinomaBeata Herberger, Harald Puhalla, Martina Lehnert, et al.
Pancreas|June 19, 2013
Molecularly targeted therapies in metastatic pancreatic cancer: a systematic reviewFlora Zagouri, Theodoros N Sergentanis, Dimosthenis Chrysikos, et al.
Clinical Medicine Insights. Oncology|March 1, 2021
Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC PatientsKlaus Hackner, Anna Buder, Maximilian J Hochmair, et al.
Targeted Oncology|February 28, 2019
EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCRAnna Buder, Ulrike Setinek, Maximilian J Hochmair, et al.
Targeted Oncology|December 13, 2018
Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to OsimertinibMaximilian J Hochmair, Anna Buder, Sophia Schwab, et al.
Current Opinion in Oncology|November 13, 2019
Beyond tissue biopsy: a diagnostic framework to address tumor heterogeneity in lung cancerWieland Voigt, Christian Manegold, Lothar Pilz, et al.
Pageof 13

Showing results (31-40 of 122) with videos related to

Sort By:
Pageof 13
Scientific Reports|January 24, 2017
Electronic State of Sodium trans-[Tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) in Tumor, Liver and Kidney Tissue of a SW480-bearing MouseAmir Blazevic, Alfred A Hummer, Petra Heffeter, et al.
Molecular Cancer Therapeutics|June 11, 2009
Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cellsBeata Herberger, Walter Berger, Harald Puhalla, et al.
The British Journal of Oral & Maxillofacial Surgery|August 15, 2012
Impact of epidermal growth factor receptor, mesenchymal-epithelial transition factor, and insulin-like growth factor receptor 1 expression on survival of patients with oral and oropharyngeal cancerChristos Perisanidis, Fritz Wrba, Anita Brandstetter, et al.
Clinical Breast Cancer|July 2, 2013
Pertuzumab in breast cancer: a systematic reviewFlora Zagouri, Theodoros N Sergentanis, Dimosthenis Chrysikos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinomaBeata Herberger, Harald Puhalla, Martina Lehnert, et al.
Pancreas|June 19, 2013
Molecularly targeted therapies in metastatic pancreatic cancer: a systematic reviewFlora Zagouri, Theodoros N Sergentanis, Dimosthenis Chrysikos, et al.
Clinical Medicine Insights. Oncology|March 1, 2021
Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC PatientsKlaus Hackner, Anna Buder, Maximilian J Hochmair, et al.
Targeted Oncology|February 28, 2019
EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCRAnna Buder, Ulrike Setinek, Maximilian J Hochmair, et al.
Targeted Oncology|December 13, 2018
Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to OsimertinibMaximilian J Hochmair, Anna Buder, Sophia Schwab, et al.
Current Opinion in Oncology|November 13, 2019
Beyond tissue biopsy: a diagnostic framework to address tumor heterogeneity in lung cancerWieland Voigt, Christian Manegold, Lothar Pilz, et al.
Pageof 13